LeMaitre Vascular Inc (NASDAQ:LMAT) has received an average recommendation of “Buy” from the eleven ratings firms that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $33.25.

LMAT has been the subject of a number of research reports. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Wednesday, July 29th. Stifel Nicolaus upped their price target on shares of LeMaitre Vascular from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. TheStreet raised shares of LeMaitre Vascular from a “c” rating to a “b-” rating in a report on Thursday, August 13th. Finally, BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, September 11th.

LMAT traded up $0.65 on Friday, reaching $32.79. The company’s stock had a trading volume of 9,927 shares, compared to its average volume of 135,605. The company has a market capitalization of $650.10 million, a price-to-earnings ratio of 39.68, a P/E/G ratio of 4.02 and a beta of 1.37. LeMaitre Vascular has a fifty-two week low of $18.76 and a fifty-two week high of $38.64. The company has a quick ratio of 1.03, a current ratio of 2.07 and a debt-to-equity ratio of 0.24. The stock has a 50 day moving average of $30.34 and a two-hundred day moving average of $27.20.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.16. LeMaitre Vascular had a net margin of 14.36% and a return on equity of 11.13%. The business had revenue of $24.85 million during the quarter, compared to analysts’ expectations of $15.58 million. As a group, analysts anticipate that LeMaitre Vascular will post 0.77 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Thursday, August 27th were given a $0.095 dividend. The ex-dividend date of this dividend was Wednesday, August 26th. This represents a $0.38 dividend on an annualized basis and a yield of 1.16%. LeMaitre Vascular’s payout ratio is currently 43.18%.

In related news, Director David B. Roberts purchased 7,074 shares of the stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $28.35 per share, with a total value of $200,547.90. Following the purchase, the director now directly owns 43,557 shares in the company, valued at approximately $1,234,840.95. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Trent G. Kamke sold 13,804 shares of the stock in a transaction dated Friday, July 24th. The shares were sold at an average price of $33.00, for a total transaction of $455,532.00. Following the completion of the transaction, the insider now owns 21,558 shares of the company’s stock, valued at approximately $711,414. The disclosure for this sale can be found here. Insiders own 16.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC boosted its position in LeMaitre Vascular by 4.8% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,802,869 shares of the medical instruments supplier’s stock worth $47,596,000 after purchasing an additional 81,788 shares during the period. State Street Corp raised its stake in shares of LeMaitre Vascular by 2.2% during the first quarter. State Street Corp now owns 670,603 shares of the medical instruments supplier’s stock valued at $16,711,000 after purchasing an additional 14,244 shares during the period. Copeland Capital Management LLC lifted its position in shares of LeMaitre Vascular by 6.4% during the second quarter. Copeland Capital Management LLC now owns 641,351 shares of the medical instruments supplier’s stock worth $16,932,000 after purchasing an additional 38,406 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of LeMaitre Vascular by 1.2% in the first quarter. Russell Investments Group Ltd. now owns 453,233 shares of the medical instruments supplier’s stock valued at $11,290,000 after purchasing an additional 5,411 shares during the period. Finally, Geode Capital Management LLC increased its stake in LeMaitre Vascular by 5.6% during the 1st quarter. Geode Capital Management LLC now owns 272,185 shares of the medical instruments supplier’s stock worth $6,782,000 after buying an additional 14,468 shares during the period. 83.61% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: Federal Reserve

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.